Epsilon Imaging Receives CE Mark For EchoInsight Visualization, Analysis Platform
ANN ARBOR (WWJ) -- Epsilon Imaging Inc., a visualization and analysis software provider transforming cardiac diagnostic workflow, announced it has received the CE mark for its EchoInsight visualization and analysis platform with practical strain imaging for improved quality, standardization and workflow in echo interpretation.
The CE mark will allow EchoInsight to be sold in the European Union nations. EchoInsight has already been approved by the United States Food and Drug Administration.
By assisting clinicians to quickly and easily integrate strain imaging into the clinical environment, EchoInsight enables improved analysis and interpretation of studies. EchoInsight provides immediate access to analysis, intuitive features and clinically specific applications with straightforward information to improve confidence in function assessment based on study type. The platform offers customized integration to customer healthcare IT workflow as a DICOM compliant platform, along with premier remote customer support.
EchoInsight's platform standard features include automated processing, rapid review and study comparison, efficient endocardial border tracing, intuitive visualization and analysis, click-of-a-button wall motion assessment based on recognized standards, automatic calculation of cardiac function measurements and concise, visual-based reporting with PACS archival ability.
Initial customized clinical applications include:
•EchoInsight for Stress Echo with features including rapid rest-stress study comparison, and global and regional wall and chamber function analysis based on strain and Ejection Fraction (EF).
•EchoInsight for Cardio Oncology with features including rapid serial study comparison, and global and regional longitudinal strain and EF trending with percent change from baseline.
At ASE '13, a University of Chicago Medicine study was presented demonstrating EchoInsight for Cardio Oncology to be a high quality, efficient application for comprehensive assessment of changes in function in the left ventricle of the heart. The study further suggests EchoInsight for Cardio Oncology may improve monitoring of patients at risk for cardiotoxicity. Learn more at http://epsilon-imaging.com/documents/ase2013_univofchi613.pdf.
More at www.epsilon-imaging.com.
